Nanobiotix updates voting rights and share capital
Nanobiotix S.A. reports its share capital and voting rights as of May 31, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Nanobiotix S.A. reports its share capital and voting rights as of May 31, 2026. The company lists 50,807,903 shares outstanding, with total theoretical voting rights of 54,304,858 and total exercisable voting rights of 54,282,740.
Theoretical voting rights include all shares with attached voting rights, even when suspended, and are used to calculate regulatory threshold crossings in France. Exercisable voting rights exclude shares with suspended voting rights, such as treasury shares, to reflect the votes that can actually be cast at a shareholders’ meeting.
Key Figures
Shares outstanding: 50,807,903 shares
Total theoretical voting rights: 54,304,858 voting rights
Total exercisable voting rights: 54,282,740 voting rights
+1 more
4 metrics
Shares outstanding
50,807,903 shares
As of May 31, 2026
Total theoretical voting rights
54,304,858 voting rights
As of May 31, 2026; basis for threshold calculations
Total exercisable voting rights
54,282,740 voting rights
As of May 31, 2026; votes that can be cast
Reporting date
May 31, 2026
Date of share capital and voting rights data
Key Terms
theoretical voting rights, exercisable voting rights, French Commercial Code, Autorité des Marchés Financiers, +1 more
5 terms
theoretical voting rights financial
"The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings."
Theoretical voting rights are the share of control an investor would have if all possible sources of additional shares—such as stock options, warrants and convertible bonds—were turned into ordinary shares. Investors care because this “what-if” number shows potential dilution of current owners and the maximum voting power others could gain, helping assess control risk and how future actions might change company decisions, like a snapshot of ownership if every coupon were cashed in.
exercisable voting rights financial
"The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended."
Exercisable voting rights are the actual, usable votes attached to a security or position that allow the holder to influence company decisions at shareholder meetings—for example electing the board or approving mergers. They matter to investors because the number of votes someone can cast determines who controls the company and its strategy, similar to having usable tickets at a town meeting rather than placeholders, and can affect share value, takeover risk and how much influence minority holders have.
French Commercial Code regulatory
"In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority"
The French Commercial Code is the national rulebook that sets the legal framework for business activity in France, covering company formation and governance, commercial contracts, trade practices, bankruptcy procedures and the role of commercial courts. For investors, it matters because these rules determine how companies are structured, how contracts and disputes are handled, and how creditor and shareholder rights are protected — like an operating manual that shapes business risk and legal recourse.
Autorité des Marchés Financiers regulatory
"and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)"
Autorité des marchés financiers is the French-language name for an independent government agency that supervises and enforces rules for securities markets, financial firms, and investor protection. It matters to investors because it requires companies to publish accurate information, polices fraud and insider trading, and can suspend trading or impose penalties—acting like a referee and safety inspector to help markets stay fair and reliable and to give investors confidence and recourse.
nanotechnology platforms technical
"Nanobiotix is the owner of more than 30 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What voting rights did Nanobiotix (NBTX) report for May 31, 2026?
Nanobiotix reported 54,304,858 theoretical voting rights and 54,282,740 exercisable voting rights as of May 31, 2026. Theoretical rights include all shares with attached votes, while exercisable rights exclude shares with suspended voting rights, such as treasury shares.
What is the difference between theoretical and exercisable voting rights at Nanobiotix?
Theoretical voting rights include all shares with attached votes, even when suspended. Exercisable voting rights exclude shares with suspended voting rights, such as treasury shares, and therefore represent the votes that can actually be cast at a shareholders’ meeting.
On which markets is Nanobiotix (NBTX) listed?
Nanobiotix is listed on Euronext Paris, in Compartment B, and on the Nasdaq Global Select Market under the symbol NBTX. These dual listings give the company access to both European and U.S. equity investors for trading its shares.
What type of company is Nanobiotix and where is it based?
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France. It focuses on physics-based nanotechnology platforms with applications in oncology, bioavailability and biodistribution, and central nervous system disorders, and also operates a subsidiary in Cambridge, Massachusetts.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates